Skip to main content
Top
Published in: Diabetologia 6/2009

01-06-2009 | Article

Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis

Authors: C. C. Lee, A. I. Adler, M. S. Sandhu, S. J. Sharp, N. G. Forouhi, S. Erqou, R. Luben, S. Bingham, K. T. Khaw, N. J. Wareham

Published in: Diabetologia | Issue 6/2009

Login to get access

Abstract

Aims/hypothesis

We examined the association between serum C-reactive protein (CRP) and incident diabetes in a prospective study, and added these data to a literature-based meta-analysis to explore potential sources of heterogeneity between studies.

Methods

We analysed a case–control study nested within the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort, including 293 incident diabetes cases and 708 controls. We combined 16 published studies on CRP and incident diabetes in a random-effect meta-analysis.

Results

In the EPIC-Norfolk cohort, serum CRP was associated with a higher risk of diabetes after adjusting for age, sex, BMI, family history of diabetes, smoking and physical activity (OR 1.49, comparing the extreme thirds of CRP distribution [95% CI 1.03–2.15], p = 0.03). However, the association was completely attenuated after further adjustment for WHR, serum γ-glutamyltransferase and serum adiponectin (OR 1.00; 95% CI 0.66–1.51, p = 1.0). In a meta-analysis of 16 published studies with 3,920 incident diabetes cases and 24,914 controls, the RR was 1.72 (95% CI 1.54–1.92), comparing the extreme thirds of CRP distribution, with substantial heterogeneity between studies (I 2 = 52.8%, p = 0.007).

Conclusions/interpretation

Initial evidence of association between CRP and incident diabetes was confounded by central adiposity, markers of liver dysfunction and adiponectin in the primary analysis. Despite an overall positive association in the meta-analysis, considerable heterogeneity existed between studies. The degree of adjustment for central adiposity and baseline glycaemia explained some of this heterogeneity and suggests that CRP may not be an independent risk factor for type 2 diabetes.
Literature
1.
go back to reference Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248PubMedCrossRef Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248PubMedCrossRef
2.
go back to reference Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedCrossRef Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedCrossRef
3.
go back to reference Dehghan A, Kardys I, de Matt MPM et al (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56:872–878PubMedCrossRef Dehghan A, Kardys I, de Matt MPM et al (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56:872–878PubMedCrossRef
4.
go back to reference Doi Y, Kiyohara Y, Kubo M et al (2005) Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population. Diabetes Care 28:2497–2500PubMedCrossRef Doi Y, Kiyohara Y, Kubo M et al (2005) Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population. Diabetes Care 28:2497–2500PubMedCrossRef
5.
go back to reference Laaksonen DE, Niskanen L, Nyyssonen K et al (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47:1403–1410PubMedCrossRef Laaksonen DE, Niskanen L, Nyyssonen K et al (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47:1403–1410PubMedCrossRef
6.
go back to reference Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693–700PubMedCrossRef Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693–700PubMedCrossRef
7.
go back to reference Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N (2003) Elevated C-reactive protein is risk factor for the development of type 2 diabetes in Japanese American. Diabetes Care 26:2754–2757PubMedCrossRef Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N (2003) Elevated C-reactive protein is risk factor for the development of type 2 diabetes in Japanese American. Diabetes Care 26:2754–2757PubMedCrossRef
8.
go back to reference Spranger J, Kroke A, Mohlig M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes 52:812–817PubMedCrossRef Spranger J, Kroke A, Mohlig M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes 52:812–817PubMedCrossRef
9.
go back to reference Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596–1600PubMedCrossRef Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596–1600PubMedCrossRef
10.
go back to reference Barzilay JI, Abraham L, Heckbert SR et al (2001) The relation of markers of inflammation to the development of glucose disorders in the elderly. The Cardiovascular Health Study. Diabetes 50:2384–2389PubMedCrossRef Barzilay JI, Abraham L, Heckbert SR et al (2001) The relation of markers of inflammation to the development of glucose disorders in the elderly. The Cardiovascular Health Study. Diabetes 50:2384–2389PubMedCrossRef
11.
go back to reference Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef
12.
go back to reference Thorand B, Lowel H, Schneider A et al (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men. Arch Intern Med 163:93–99PubMedCrossRef Thorand B, Lowel H, Schneider A et al (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men. Arch Intern Med 163:93–99PubMedCrossRef
13.
go back to reference Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes 52:1799–1805PubMedCrossRef Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes 52:1799–1805PubMedCrossRef
14.
go back to reference Festa A, D’Agostino R, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 51:1131–1137PubMedCrossRef Festa A, D’Agostino R, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 51:1131–1137PubMedCrossRef
15.
go back to reference Krakoff J, Funahashi T, Stehouwer CDA et al (2003) Inflammatory markers, adiponectin and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–1751PubMedCrossRef Krakoff J, Funahashi T, Stehouwer CDA et al (2003) Inflammatory markers, adiponectin and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–1751PubMedCrossRef
16.
go back to reference Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM (2002) Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016–2021PubMedCrossRef Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM (2002) Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016–2021PubMedCrossRef
17.
go back to reference Snijder M, Dekker JM, Visser M et al (2003) Prospective relation of C-reactive protein with type 2 diabetes. Diabetes Care 26:1656–1657PubMedCrossRef Snijder M, Dekker JM, Visser M et al (2003) Prospective relation of C-reactive protein with type 2 diabetes. Diabetes Care 26:1656–1657PubMedCrossRef
18.
go back to reference Thorand B, Baumert J, Kolb H et al (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers. Result from the MONICA/KORA Augsburg case–cohort study, 1984–2002. Diabetes Care 30:854–860PubMedCrossRef Thorand B, Baumert J, Kolb H et al (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers. Result from the MONICA/KORA Augsburg case–cohort study, 1984–2002. Diabetes Care 30:854–860PubMedCrossRef
19.
go back to reference Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef
20.
go back to reference Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228PubMedCrossRef Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228PubMedCrossRef
21.
go back to reference Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes. Diabetes 53:2473–2478PubMedCrossRef Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes. Diabetes 53:2473–2478PubMedCrossRef
22.
go back to reference Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J (2004) Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 89:5410–5414PubMedCrossRef Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J (2004) Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 89:5410–5414PubMedCrossRef
23.
go back to reference Nannipieri M, Gonzales C, Baldi S et al (2005) Liver enzymes, the metabolic syndrome and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 28:1757–1762PubMedCrossRef Nannipieri M, Gonzales C, Baldi S et al (2005) Liver enzymes, the metabolic syndrome and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 28:1757–1762PubMedCrossRef
24.
go back to reference Andre P, Balkau B, Born C, Charles MA, Eschwege E (2006) Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the DESIR cohort. Diabetologia 49:2599–2603PubMedCrossRef Andre P, Balkau B, Born C, Charles MA, Eschwege E (2006) Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the DESIR cohort. Diabetologia 49:2599–2603PubMedCrossRef
25.
go back to reference Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27:1680–1687PubMedCrossRef Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27:1680–1687PubMedCrossRef
26.
go back to reference Lee DH, Jacobs DR Jr (2005) Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 178:327–330PubMedCrossRef Lee DH, Jacobs DR Jr (2005) Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 178:327–330PubMedCrossRef
27.
go back to reference Day N, Oakes S, Luben R et al (1999) EPIC-Norfolk: study design, characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80(Suppl 1):95–103PubMed Day N, Oakes S, Luben R et al (1999) EPIC-Norfolk: study design, characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80(Suppl 1):95–103PubMed
28.
go back to reference Harding AH, Day NE, Khaw KT et al (2004) Dietary fat and the risk of clinical type 2 diabetes: the European Prospective of Cancer—Norfolk Study. Am J Epidemiol 159:73–82PubMedCrossRef Harding AH, Day NE, Khaw KT et al (2004) Dietary fat and the risk of clinical type 2 diabetes: the European Prospective of Cancer—Norfolk Study. Am J Epidemiol 159:73–82PubMedCrossRef
29.
go back to reference Forouhi NG, Harding AH, Allison M et al (2007) Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50:949–956PubMedCrossRef Forouhi NG, Harding AH, Allison M et al (2007) Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50:949–956PubMedCrossRef
30.
go back to reference Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA 279:1477–1482PubMedCrossRef Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA 279:1477–1482PubMedCrossRef
31.
go back to reference Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327:557–560PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327:557–560PubMedCrossRef
32.
go back to reference Yoneda M, Mawatari H, Fujita K et al (2007) High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 42:573–582PubMedCrossRef Yoneda M, Mawatari H, Fujita K et al (2007) High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 42:573–582PubMedCrossRef
33.
go back to reference Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA (2000) Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 248:230–238PubMedCrossRef Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA (2000) Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 248:230–238PubMedCrossRef
34.
go back to reference Kang YH, Min HK, Son SM, Kim IJ, Kim YK (2007) The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract 77:306–313PubMedCrossRef Kang YH, Min HK, Son SM, Kim IJ, Kim YK (2007) The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract 77:306–313PubMedCrossRef
35.
go back to reference Sakugawa H, Nakayoshi T, Kobashigawa K et al (2004) Metabolic syndrome is directly associated with gamma glutamyl transpeptidase elevation in Japanese women. World J Gastroenterol 10:1052–1055PubMed Sakugawa H, Nakayoshi T, Kobashigawa K et al (2004) Metabolic syndrome is directly associated with gamma glutamyl transpeptidase elevation in Japanese women. World J Gastroenterol 10:1052–1055PubMed
36.
go back to reference Yuan G, Chen X, Ma Q et al (2007) C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 194:275–281PubMedCrossRef Yuan G, Chen X, Ma Q et al (2007) C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 194:275–281PubMedCrossRef
37.
go back to reference Hamdy O, Porramatikul S, Al-Ozairi E (2006) Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2:367–373PubMed Hamdy O, Porramatikul S, Al-Ozairi E (2006) Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2:367–373PubMed
38.
go back to reference Greenfield JR, Samaras K, Jenkins AB et al (2004) Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 109:3022–3028PubMedCrossRef Greenfield JR, Samaras K, Jenkins AB et al (2004) Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 109:3022–3028PubMedCrossRef
39.
go back to reference Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD (2002) Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with type 2 diabetes. Diabet Med 19:847–852PubMedCrossRef Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD (2002) Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with type 2 diabetes. Diabet Med 19:847–852PubMedCrossRef
40.
go back to reference Meier-Ewert HK, Ridker PM, Rifai N et al (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47:426–430PubMed Meier-Ewert HK, Ridker PM, Rifai N et al (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47:426–430PubMed
41.
go back to reference Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397PubMedCrossRef Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397PubMedCrossRef
Metadata
Title
Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis
Authors
C. C. Lee
A. I. Adler
M. S. Sandhu
S. J. Sharp
N. G. Forouhi
S. Erqou
R. Luben
S. Bingham
K. T. Khaw
N. J. Wareham
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1338-3

Other articles of this Issue 6/2009

Diabetologia 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.